Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy

by Yulong Fu, Yulong Fu, Anqi Wang, Anqi Wang, Jieqi Zhou, Jieqi Zhou, Wei Feng, Minhua Shi, Xiao Xu, Hongqing Zhao, Liming Cai, Jian Feng, Xuedong Lv, Xiaodong Zhang, Wenjing Xu, Zhengrong Zhang, Guoer Ma, Jian Wang, Tong Zhou, Dahai Zhao, Haohui Fang, Zeyi Liu, Zeyi Liu, Zeyi Liu, Jian-an Huang, Jian-an Huang, Jian-an Huang
Published 2021-02-01

366 A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCL...

by Jun Chen, Wei Zhang, Yu Zhang, Tao Xu, Ying Tian, Ming Zhou, Jie Jiang, Minhua Ye, Liwei Zhang, Yunpeng Liu, Wenxiang Wang, Lin Wu, Shun Lu, Haohui Fang, Guohua Yu, Wenqun Xing, Qixun Chen, Xingya Li, Nong Yang, Wentao Fang, Yunchao Huang, Jichun Liu, Lijie Tan, Xiaosheng Hang, Wengang Zhang, Xun Zhang, Aihong Zhong, Shanqing Li, Guowu Wu, Xiaoyan Kang
Published 2020-11-01